Top ten hot topics in parenteral science and technology

PDA Journal of Pharmaceutical Science and Technology

Volumn 61, Issue 5, 2007, Pages 337-361

  Akers, Michael J ^a,b   Nail, Steven L ^a   Saffell Clemmer, Wendy ^a  

^a Pharmaceutical Research and Development   (United States)

^b Baxter BioPharma Solutions   (United States)

Author keywords

Convenience packaging; Formulation; Injectable controlled release; Liposomes; Microspheres; Monoclonal anbitodies; Nanoparticles; Nanosuspensions; Packaging; Pegylated proteins; Plastics; Prefilled syringes; Rubber closures; Silicone; Solubility

Indexed keywords

ALPRAZOLAM; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANGIOPEPTIN; ARESTIN; ASPARAGINASE MACROGOL; ATRIDOX; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BUSERELIN ACETATE; CHRONIJECT; CONSTA; CYTARABINE; DAUNORUBICIN; DECAPEPTYL LP; DOXORUBICIN; GOSERELIN; HUMAN GROWTH HORMONE; IMETRIX; INFLEXA V; LEUPRORELIN; LIPOBRIDGE; LIPOSOME; LUPROGEL; LYOTEC; MEDISORB; MEVINOLIN; MICROSPHERE; MORPHINE SULFATE; MUCAGEN; OCTREOTIDE; OMNIFLEX; PARENTERAL SOLUTION; PEGADEMASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGVISOMANT; PERFLUTREN; POLYGLACTIN; POLYLACTIDE; POLYMER; PROFACT; PROMAXX; PROTEIN; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RESPIREDAL; RISPERIDAL; SABER; SPORONOX; TRIPTORELIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VERTEPORFIN; VORICONAZOLE; ZIPRASIDONE;

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG SOLUBILITY; DRUG STABILITY; MEDICAL INSTRUMENTATION; PARTICULATE MATTER; REVIEW; SCIENCE; TECHNOLOGY;

ASEPSIS; CHEMISTRY, ANALYTICAL; CHEMISTRY, PHARMACEUTICAL; DRUG CONTAMINATION; DRUG INDUSTRY; DRUG PACKAGING; EQUIPMENT DESIGN; HUMANS; INJECTIONS; MICROBIOLOGICAL TECHNIQUES; PHARMACEUTICAL PREPARATIONS; PROTEINS; QUALITY CONTROL; TECHNOLOGY, PHARMACEUTICAL;

EID: 37449006129     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Akers, M. J.; Nail, S. L. Top ten technical issues in parenteral science. PharmTech 1994, 18, 26-36.
2. Akers, M. J.; Nail, S. L.; Groves, M. J. Top ten technical issues in parenteral science - revisited, 1997. PharmTech 1997, 21, 126-136.
3. Bingham, D.; Robinson, C. A decade in review: The evolution of the drug delivery industry. Drug Delivery Technology 2006, 6 (Feb), 22-27.
4. Chaubal, M. V.; Roseman, T. J. Drug delivery trends for parenteral therapeutics. PharmTech 2006, 30 (October), 110-122.
5. www.elan.com/EDT/drug_optimization/injectable_route_admin.asp
6. Kipp, J. E. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int. J. Pharm. 2004, 284, 109-122.
7. McDonough, J.; Schlameus, W. Uncontrolled growth of controlled release drug delivery technology and markets. Pharm. Manufacturing Packing Sourcer 2002, Autumn, 13.
8. Martini, A.; Lauria, S. Sustained release injectable products. Am. Pharm. Rev. 2003, 6 (Fall), 16-20.
9. Harrison, R. C. Development and applications of long-acting injection formulations. Drug Del. Tech. 2006, 6 (July/August), 36-40.
10. Tice, T. Delivering with depot formulations. Drug Del. Tech. 2004, 4, (January/February), 44-47.
11. Dunn, R. Application of ATRIGEL® implant drug delivery technology for patient-friendly, cost-effective product development. Drug Del. Tech. 2003, 3 (September), 38-43.
12. Verrijk, R.; Gos, B.; Crommelin, B. J. A.; Hennink, W. Controlled release of pharmaceutical proteins from hydrogels. Pharm. Manufacturing Packing Sourcer 2003, Summer, 27-33.
13. Brown, L.; Qin, Y.; Hogeland, K.; McGeehan, J.; Mason, K.; Jeannotte, T.; Fortier, R.; Moore, E. Chapter 22. Water-Soluble Formation of Monodispersed Insulin Microspheres. In Polymeric Drug Delivery II, Polymeric Matrices and Drug Particle Engineering, ACS Symposium Series 924; Svenson, S., Ed.; American Chemical Society: Washington, DC, 2006.
14. Johns, G.; Corbo, G.; Thanoo, B. C.; Maskiewicz, R. Broad applicability of a continuous formulation process for manufacture of sustained-release injectable microspheres. Drug Del. Tech. 2004, 4 (January/February), 60-63.
15. Reimer, D.; Eastman, S.; Flowers, C.; Boey, A.; Redelmeier, T.; Ouyang, C. Liposome formulations of sparingly soluble compounds: Liposome technology offers many advantages for formulation of sparingly soluble compounds. Pharm. Formulation and Technol. 2005, August/September, 42-44; http://www.pharmaquality.com/mag/08092005/pfq_08092005_FO2.html
16. http://www.brightsurf.com/news/june_04/AACR_news_060104.php
17. Paulson, H. RNA interference as potential therapy for neurodegenerative disease. Neurobiology 2006, 66, S114-S117.
18. Morar, A. S.; Schrimsher, J. L.; Chavez, M. D. PEGylation of proteins: A structural approach. BioPharm Int. 2006, 19 (4), 34-49.
19. Please consult websites of companies listed in this section for additional information about their products.
20. Polin, J. B. The ins and outs of prefilled syringes. Pharm. Manufacturing Packing News 2003, May; also http://www.devicelink.com/grabber.php3?URL=http://www.devicelink.com/pmpn/ archive/03/05/001.html
21. Polin, J. B. The evolution of parenteral drug packaging. Pharm. Manufacturing Packing News 2004, March; also http://www.devicelink.com/grabber.php3?URL=http://www.devicelink.com/pmpn/ archive/04/03/001.html
22. Kauffman, J. S. Identification and risk-assessment of extractables and leachables. PharmTech 2006, 30 (Analytical Methods Supplement), s16-s22.
23. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products, ICH Q6A.
24. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Container Closure Systems for Packaging Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Documentation May 1999; p 23.
25. Zimmerman, J. A.; Ballard, J. M.; Wang, H.; Wu, A.; Gallagher, K. A. Extraction of 0-phenylphenol from silicone tubing by a sulfobutylether cyclodextrin formulation. Int. J. Pharm. 2003, 267, 113-120.
26. Sharma, B.; Bader, F.; Templeman, T.; Lisi, P.; Ryan, M.; Heavner, G. Technical investigations into the cause of the increased incidence of antibody-mediated pure red cell aplasia associated with Eprex®. Eur. J. Hosp. Pharm. 2004, 12, 88-91.
27. Castner, J.; Williams, N.; Bresnick, M. Leachables found in parenteral drug products. Am. Pharm. Rev. 2004, 7 (March/April), 70-75.
28. 2005 PQRI Leachables and Extractables Forum, Bethesda, MD, December 2005.
29. Dave, K. J. ITFG/IPAC Technical Team: CMC Leachables and Extractables, www.fda/gov/ohrms/dockets/ac/00/slides/3609s1o.ppt
30. Cleland, J. L.; Powell, M. F.; Shire, S. J. The development of stable protein formulations. Crit. Rev. Ther. Drug Carrier Sys. 1993, 10 (4), 307-377.
31. Perez-Ramirez, B.; Steckert, J. Probing Reversible Self-Association of Therapeutic Proteins by Sedimentation Velocity in the Analytical Ultracentrifuge. In Methods in Molecular Biology, 308: Therapeutic Proteins: Methods and Protocols; Smales, C. M., James, D. C., Eds.; Humana Press Inc.: Totowa, NJ, 2005; pp 301-318.
32. Kirshner, S. FDA Perspective: Current U.S. Regulatory Issues in Validation. IBC Conference on Analytical Method Validation, Reston, VA, July 17, 2006.
33. Rosenberg, A. Overview: Significance of Protein Aggregation to Therapeutic protein products. FDA Public Workshop: Scientific Issues in Assessing the Similarity of Follow-on Protein Products, New York Academy of Sciences, Brooklyn, NY, December 13, 2005.
34. Karunatilake, C. Oligomeric Structure Analytical Technologies: Assessment of Oligomeric Structure of gp-140 using SEC-MALS, FFF-MALS, and Native-PAGE. Workshop on Protein Aggregation, Breckenridge, CO, September 26 2006.
35. Cromwell, M. Detecting Aggregation, AAPS Annual Meeting, San Antonio, TX, October 31, 2006.
36. Ye, H. Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle light scattering. Anal. Biochem. 2006, 356 (1), 76-85.
37. Fraunhofer, W; Winter, G. The use for asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur. J. Pharm. Biopharm. 2004, 58 (2), 369-383.
38. Liu, J.; Andya, J.; Shire, S. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS Journal 2006, 8 (3), E580-E589.
39. Mahler, H.-C.; Muller, R.; Frie, W.; Delille, A.; Matheus, S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur. J. Pharm. Biopharm. 2005, 59 (3), 407-417.
40. Philo, J. Ultracentrifugation. In The Biopharm Guide to Bioanalytical Methods, Supplement to BioPharm, pp.52-54, Dec 2001.
41. Guidance for Industry on Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations. Federal Register, 71 (October 2, 2006), 57980.
42. PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance, September 2004; http://www.fda.gov/cder/ guidance/6419fnl.htm
43. Kudryashov, E.; O'Driscoll, B. Benefits of high-resolution ultrasonic spectroscopy in a PAT installation. Pharmaceutical Processing 2006, September, 26-32.
44. Gieseler, H.; Kessler, W. J.; Finson, M.; Davis, S. J.; Mulhall, P. A.; Bons, V; Debo, D. J.; Pikal, M. J. Evaluation of tunable diode laser absorption spectroscopy for in-process water vapor mass flux measurements during freeze drying. J. Pharm. Sci. 2007, 96 (7), 1776-1793.
45. Aranha, H. Disposable systems. BioProcess Int. 2004, October (Supplement), 6-16.
46. Pora, H., Simplifying validation of disposable technologies with presterilization by gamma irradiation, Guide to advances in bioprocessing: Disposables. BioPharm Int. 2006, November (Supplement), 2006, p. 36.
47. Blanck, R. Disposable filling - A new trend for sterile pharmaceuticals. Pharm. Manufacturing Packing Sourcer 2002, Autumn, 34-36.
48. Hodge, G. Disposable components enable a new approach to biopharmaceutical manufacturing. Biopharm Int. 2004, March, 38-49.
49. Samavedam, R.; Goldstein, A.; Schieche, D. Implementation of disposables: Validation and other considerations. Am. Pharm. Rev. 2006, 9 (September/October), 46-51.
50. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice, September 2004.
51. Agalloco, J.; Akers, J.; Madsen, R. Aseptic processing: A review of current industry practice. PharmTech 2004, 28 (October), 126-150.
52. Akers, J. E.; Kokubo, M.; Oshima, Y. The next generation of aseptic processing equipment. PharmTech 2006, 30 (May), http://www.pharmtech.com/pharmtech/article/articleDetail.jsp?id=322979
53. Agalloco, J. P.; Akers, J. RABS and advanced aseptic processing. PharmTech 2006, 30 (May), 2006, http://www.pharmtech.com/ pharmtech/article/articleDetail.jsp?id=322984.
54. Chiarello, K. Pharma industry drives innovation in barrier/isolation design. PharmTech 2004, 28 (March) 44-54.
55. Haughney, H.; Aranha, H. Considerations for use in aseptic processing of pharmaceuticals. PharmTech 2003, 27 (Supplement on Aseptic Processing), 16-21.
56. Nail, S. L.; Guazzo, D.; Rajagopalan, N.; Stickelmeyer, M.; Williams, T. Visual inspection of parenteral products in a development environment. Am. Pharm. Rev. 2006, 9 (September/October), 96-101.
57. Nath, N.; McNeal, E.; Obenhuber, D.; Pillari, B.; Shelton, L.; Stevens-Riley, M.; Sweeney, N. Particulate contaminants of intravenous medication and the limits set by USP Chapter 〈788〉. Pharmacopeial Forum 2004, 30, 2272-2280.